Lyon, France (ots/PRNewswire) - The European Medicine Agency's Pharmacovigilance Risk Assessment Committee (PRAC) concludes that there is no reason to change the way the vaccines are used or amend the current product information. Sanofi Pasteur MSD welcomes the European Medicine Agency's Pharmacovigilance Risk ...
Heidelberg (ots) - The BioMed X Innovation Center announced today that they have extended their current collaboration with Boehringer Ingelheim in the field of chronic obstructive pulmonary disease (COPD) to establish a second team of outstanding scientists from around the world to discover novel therapeutic ...
Ingelheim and Heidelberg (ots) - - Aims to identify of novel epigenetic drivers to find new approaches for treating COPD - Crowdsourcing used to find unconventional solutions and identify the best talent from around the world - New research team will be established at the BioMed X Innovation Center in Heidelberg, ...
ITM Isotope Technologies Munich SE
Garching (ots) - The ITM Group announced today that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next generation theranostic agent for Bone Targeted Radionuclide Therapy and Diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone ...
Heidelberg (ots) - BioMed X Innovation Center announced today that they have extended their collaboration with Merck Serono, the biopharmaceuticals business of Merck, on new approaches for cancer therapy. Based on the results presented at the biannual meeting on July 10th in Heidelberg, Germany, Merck Serono decided to extend the funding of the first two international research groups for a third year. BioMed X and Merck ...
ITM Isotope Technologies Munich SE
Garching (ots) - The ITM Group announced today that the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) of the medicinal product EndolucinBeta, a radiopharmaceutical precursor. EndolucinBeta is not intended for direct use in patients but will be used for ...
Heidelberg (ots) - Roche and BioMed X announced today that they have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene. Outstanding early career scientists from leading academic ...
Heidelberg (ots) - BioMed X announced today that they have entered into a collaboration agreement with Boehringer Ingelheim to establish a research group focusing on the identification of novel therapeutic concepts for treating patients with chronic obstructive pulmonary disease (COPD). Outstanding early career scientists from leading academic institutions world-wide ...
European Society for Medical Oncology (ESMO)
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
Asklepios Kliniken GmbH & Co. KGaA
Hamburg (ots) - - Cross reference: Additional information available at http://ots.de/taeAX - Copper has been shown to have antimicrobial properties and significantly reduce dangerous germs such as bacteria, fungi and viruses. Door handles are the most commonly used contact surfaces in hospitals. A recent on-site ...
Eckert & Ziegler Strahlen und Medizintechnik AG
Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment and is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. The cooperation enfolds a brand-new ...
The International Osteoporosis Foundation (IOF)
Nyon, Switzerland (ots) - Osteoporosis can lead to painful fractures, disability and early death, but continues to be ignored by the general public and neglected by doctors during routine physical check-ups New survey findings released on World Osteoporosis Day by the International Osteoporosis Foundation (IOF), show that on average, 90% of 13,258 adults questioned are unaware of how common osteoporotic fractures are in ...
Aachen (ots) - EMBARGO: This information is for European healthcare professionals only. Not intended for UK audience. Low back pain is one of the most common chronic pain conditions. Studies have shown that up to 85% of people worldwide will suffer from back pain during their lives.(1) A high percentage of severe ...
Nuremberg, Germany (ots) - At this year's EuroSpine Congress in Lyon, innovation leader Ziehm Imaging invites international experts to share their clinical experience in spinal neurosurgery orthopedic and traumatology. During a lunch symposium on October 1st Christoph Josten (University Hospital Leipzig), Christian Raftopoulos (Brussels Saint-Luc University Hospital) ...
Vienna, Austria (ots) - - MyStar Connect® software contributes to Sanofi's commitment in providing integrated diabetes care solutions, and supports healthcare professionals in clinical decision-making - - CE mark for MyStar Connect® - At the 50th annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the upcoming launch of ...
Aachen (ots) - - EMBARGO: This information is for healthcare professionals only. Not intended for UK audience. - A recent study published in the medical journal "Current Medical Research and Opinion"* has results that are good news for chronic pain patients. This new trial was designed to meet real-life conditions ...
LTS Lohmann Therapie-Systeme AG
Andernach (ots) - The supervisory board ("Aufsichtsrat") and management board ("Vorstand") of LTS have concluded the assessment of strategic options for the future development of the LTS group. LTS developed innovative, value oriented growth strategies identifying also the prerequisites for the successful strategy ...
Istanbul (ots) - This year's IFCC in Istanbul was a remarkable event for Sysmex. With one of our largest stands ever - showcasing the entire range of our products - we showed what we believe is living our mission of "Shaping the Advancement of Healthcare". After the IFCC we can be confident we are well on our way. The Sysmex mission is to shape the advancement of healthcare - the laboratory workflow, the diagnostic ...
Woodcliff Lake, NJ, and Lugano, Switzerland (ots) - Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed- dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting ...
Eysins (ots) - In line with its mission of market innovator, Biosafe is proud to announce the launch of the SepaMax multiprocessing device, on the occasion of the International Cord Blood Symposium in San Francisco. SepaMax is designed for high throughput cell processing. Based on Biosafe's industry-leading Sepax technology, it offers six processing modules in a compact package, which are centrally controlled. Combined ...
Singapore (ots) - Since 2012 the hearing industry's largest manufacturers have collaborated to sponsor a non-competitive, mutually agreed upon research agenda benefitting the hearing aid industry, its customers, and end users. The framework for this collaboration is the Hearing Industry Research Consortium (IRC). ...
Aachen/Brussels (ots) - Multi-stakeholder views on chronic pain presented in the European Parliament / Call to Action to fight chronic pain On the occasion of an exhibition and cocktail reception hosted by Petru Luhan, Member of the European Parliament and winner of the MEP award for Health 2013, a multi- ...
Lugano, Switzerland (ots) - The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated to improve the quality of life of people with cancer in collaboration with SDA Bocconi and CERGAS Bocconi. The combination of medicine and mobile technology to improve the quality of life of people ...
Rastatt, Landquart (ots) - MAQUET and Swisstom are pleased to announce their distribution partnership for the monitoring and diagnostic product Swisstom BB2. Acute Lung Injury is still a leading cause of death for intensive care patients. Swisstom BB2 was especially developed to continuously monitor the lung function of ICU patients undergoing mechanical ventilation. ...
Lugano, Switzerland (ots) - NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing ...
E.S.PKU (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria)
Alter, Belgium (ots) - First ever pan-European perspective on optimal care identifies key challenges in this rare genetic disease The first ever pan-European patient/carer perspective on optimal care of the rare genetic disorder phenylketonuria (PKU) has been published in the Orphanet Journal of Rare Diseases. This paper, supported by the European Society for ...
Lugano, Schweiz (ots) - Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary , Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS ...
Takeda Pharmaceuticals International GmbH
Zurich Switzerland (ots) - Takeda Pharmaceuticals International GmbH ("Takeda") announced that the European decentralised procedure (DCP) was positively concluded for dexlansoprazole, a proton pump inhibitor (PPI) with a new dual- delayed release technology for the treatment of reflux disease. The regulatory process ...
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...